JP2023513015A5 - - Google Patents
Info
- Publication number
- JP2023513015A5 JP2023513015A5 JP2022546004A JP2022546004A JP2023513015A5 JP 2023513015 A5 JP2023513015 A5 JP 2023513015A5 JP 2022546004 A JP2022546004 A JP 2022546004A JP 2022546004 A JP2022546004 A JP 2022546004A JP 2023513015 A5 JP2023513015 A5 JP 2023513015A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- week
- kras
- administered
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968615P | 2020-01-31 | 2020-01-31 | |
| US62/968,615 | 2020-01-31 | ||
| US202063115433P | 2020-11-18 | 2020-11-18 | |
| US63/115,433 | 2020-11-18 | ||
| PCT/US2021/015401 WO2021154929A1 (en) | 2020-01-31 | 2021-01-28 | Combination therapy for treating abnormal cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513015A JP2023513015A (ja) | 2023-03-30 |
| JP2023513015A5 true JP2023513015A5 (cg-RX-API-DMAC7.html) | 2024-01-22 |
Family
ID=77079417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546004A Pending JP2023513015A (ja) | 2020-01-31 | 2021-01-28 | 異常な細胞成長を処置するための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230103007A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4096671B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023513015A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230011908A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115279376A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021213753A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022015161A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3168648A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295117A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009347A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021154929A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| US20230145356A1 (en) | 2019-11-18 | 2023-05-11 | Inxmed (Nanjing) Co., Ltd. | Use of fak inhibitor in preparation of drug for treating tumors having nras mutation |
| CN115151533B (zh) | 2020-01-10 | 2025-08-08 | 医疗免疫工程公司 | Mek抑制剂及其治疗用途 |
| KR20220137666A (ko) | 2020-02-05 | 2022-10-12 | 인엑스메드 (난징) 컴퍼니 리미티드 | Bi853520과 화학요법 약물의 병용 |
| JP7836097B2 (ja) * | 2020-08-03 | 2026-03-26 | ▲應▼世生物科技(南京)有限公司 | 化合物の固体形態 |
| US20250177399A1 (en) * | 2021-01-29 | 2025-06-05 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2024521788A (ja) * | 2021-05-27 | 2024-06-04 | ミラティ セラピューティクス, インコーポレイテッド | 併用療法 |
| WO2023020291A1 (zh) | 2021-08-16 | 2023-02-23 | 应世生物科技(南京)有限公司 | In10018与pld的联用 |
| CN114133355B (zh) * | 2021-11-29 | 2023-09-15 | 郑州大学第一附属医院 | 一种2-苯基-1h-苯并咪唑类衍生物及其应用 |
| WO2023104151A1 (zh) * | 2021-12-10 | 2023-06-15 | 应世生物科技(南京)有限公司 | 治疗肿瘤的药物组合及用途 |
| EP4444310A4 (en) * | 2021-12-10 | 2025-11-19 | Verastem Inc | POLYTHERAPY FOR THE TREATMENT OF ABNORMAL CELL GROWTH |
| CN118574825A (zh) * | 2022-02-28 | 2024-08-30 | 微境生物医药科技(上海)有限公司 | 作为fak抑制剂的化合物及其用途 |
| WO2023204259A1 (ja) * | 2022-04-20 | 2023-10-26 | 中外製薬株式会社 | がんの治療又は予防用医薬 |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| JP2025520715A (ja) * | 2022-06-24 | 2025-07-03 | ▲應▼世生物科技(南京)有限公司 | 腫瘍を処置するための組合せ医薬及びその使用 |
| EP4578449A4 (en) * | 2022-08-24 | 2026-01-21 | Inxmed Nanjing Co Ltd | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND MICROTUBULE INHIBITOR AND COMBINED USE |
| EP4595963A4 (en) * | 2022-09-30 | 2026-01-21 | Inxmed Nanjing Co Ltd | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE TO INDUCE IMMUNOGENEOUS CELL DEATH AND USE |
| US20260216199A1 (en) * | 2023-01-06 | 2026-07-30 | Erasca, Inc. | Raf inhibitor and kras g12c inhibitor combination therapy |
| CN115845065A (zh) * | 2023-01-09 | 2023-03-28 | 江苏省原子医学研究所 | Fn/fak通路抑制剂在制备提高甲状腺癌放射性碘治疗敏感性的药物中的用途 |
| US12254987B2 (en) * | 2023-03-23 | 2025-03-18 | Certis Oncology Solutions, Inc. | Artificial intelligence for identifying one or more predictive biomarkers |
| EP4691487A4 (en) * | 2023-03-31 | 2026-07-22 | Inxmed Nanjing Co Ltd | METHOD FOR INCREASING THE CONCENTRATION OF A MACROMOLECULAR DRUG IN TUMOR TISSUE |
| WO2025079712A1 (ja) * | 2023-10-12 | 2025-04-17 | 中外製薬株式会社 | ドライバー変異を有するがん患者における分子標的薬併用療法 |
| WO2025106901A1 (en) * | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor |
| WO2025149017A1 (zh) * | 2024-01-11 | 2025-07-17 | 四川弘合生物科技有限公司 | 一种包含榄香烯和激酶抑制剂的药物 |
| WO2025157162A1 (zh) * | 2024-01-22 | 2025-07-31 | 应世生物科技(南京)有限公司 | Fak抑制剂与kras g12c抑制剂的联用 |
| WO2025261307A1 (zh) * | 2024-06-17 | 2025-12-26 | 首药控股(北京)股份有限公司 | 治疗肿瘤的药物组合及用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105163584B (zh) * | 2013-03-05 | 2019-06-04 | 田纳西大学研究基金会 | 用于治疗癌症的化合物 |
| ES2779975T3 (es) * | 2014-02-07 | 2020-08-21 | Verastem Inc | Métodos y composiciones para tratar el crecimiento celular anormal |
| EA201890161A1 (ru) * | 2015-06-29 | 2018-06-29 | Верастэм, Инк. | Терапевтические композиции, комбинации и способы применения |
| US11286469B2 (en) * | 2017-11-09 | 2022-03-29 | Wisconsin Alumni Research Foundation | Combination chemotherapy for the treatment of cancer |
| US20200038513A1 (en) * | 2018-07-26 | 2020-02-06 | Arvinas Operations, Inc. | Modulators of fak proteolysis and associated methods of use |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| WO2021108682A1 (en) * | 2019-11-27 | 2021-06-03 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
-
2021
- 2021-01-28 IL IL295117A patent/IL295117A/en unknown
- 2021-01-28 AU AU2021213753A patent/AU2021213753A1/en not_active Abandoned
- 2021-01-28 KR KR1020227030021A patent/KR20230011908A/ko not_active Ceased
- 2021-01-28 CN CN202180012207.9A patent/CN115279376A/zh active Pending
- 2021-01-28 WO PCT/US2021/015401 patent/WO2021154929A1/en not_active Ceased
- 2021-01-28 EP EP21747362.8A patent/EP4096671B1/en active Active
- 2021-01-28 BR BR112022015161A patent/BR112022015161A2/pt unknown
- 2021-01-28 US US17/795,402 patent/US20230103007A1/en active Pending
- 2021-01-28 MX MX2022009347A patent/MX2022009347A/es unknown
- 2021-01-28 JP JP2022546004A patent/JP2023513015A/ja active Pending
- 2021-01-28 CA CA3168648A patent/CA3168648A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023534009A5 (cg-RX-API-DMAC7.html) | ||
| EP4337191B1 (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| JP2023523323A5 (cg-RX-API-DMAC7.html) | ||
| JP2024526145A5 (cg-RX-API-DMAC7.html) | ||
| JP2022009090A5 (cg-RX-API-DMAC7.html) | ||
| JP2024540015A5 (cg-RX-API-DMAC7.html) | ||
| JP2017505321A5 (cg-RX-API-DMAC7.html) | ||
| JP2019532051A5 (cg-RX-API-DMAC7.html) | ||
| JP2024528039A5 (cg-RX-API-DMAC7.html) | ||
| Ji et al. | Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis | |
| JP2024527109A5 (cg-RX-API-DMAC7.html) | ||
| JP2019510785A5 (cg-RX-API-DMAC7.html) | ||
| JP2020536048A5 (cg-RX-API-DMAC7.html) | ||
| JP2023553533A5 (cg-RX-API-DMAC7.html) | ||
| Lee et al. | Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer | |
| CN119497618A (zh) | 药物组合产品以及组合疗法 | |
| Zhang et al. | Successful treatment of ovarian cancer with apatinib combined with chemotherapy: a case report | |
| JP7278405B2 (ja) | 小細胞肺がんの治療におけるキアウラニブの使用 | |
| CN117357534A (zh) | 包含维甲酸的药物组合物在制备治疗肝细胞癌伴腹腔转移的药物中的用途 | |
| CA3100422A1 (en) | Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3 | |
| CN104936585A (zh) | 包括苯肾上腺素和扑热息痛的组合药剂 | |
| CN110585429B (zh) | 酪氨酸激酶抑制剂联合单克隆抗体以及紫杉醇类药物治疗肿瘤疾病的用途 | |
| KR20220088700A (ko) | 국소 진행성 편평 상피 세포 암종을 가진 환자를 치료하기 위한 투여 용법 | |
| Huerta et al. | Oxaliplatin as a radiosensitizing agent in rectal cancer | |
| JPWO2015152407A1 (ja) | 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |